Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Masaki ShimizuMao MizutaNami OkamotoTakahiro YasumiNaomi IwataHiroaki UmebayashiYuka OkuraNoriko KinjoTomohiro KubotaYasuo NakagishiKenichi NishimuraMariko MohriMasato YashiroJunko YasumuraHiroyuki WakiguchiMasaaki MoriPublished in: Pediatric rheumatology online journal (2020)
TCZ could modify the clinical and laboratory features of s-JIA-associated MAS. When evaluating the s-JIA patients while treated with TCZ, it is not applicable to use MAS classification criteria. Care must be taken to not underdiagnose MAS based on the MAS classification criteria.
Keyphrases
- juvenile idiopathic arthritis
- end stage renal disease
- disease activity
- machine learning
- newly diagnosed
- deep learning
- ejection fraction
- healthcare
- chronic kidney disease
- rheumatoid arthritis
- prognostic factors
- peritoneal dialysis
- palliative care
- adipose tissue
- systemic lupus erythematosus
- quality improvement
- patient reported
- chronic pain
- drug induced